### Amoxicillin

**Section:** 6. Anti-infective medicines  >  6.2. Antibacterials  >  6.2.1. Access group antibiotics

**Indication:** Acute sinusitis  
**ICD11 code:** CA01

**INN:** Amoxicillin

**Medicine type:** Chemical agent

**Antibiotic groups:** ACCESS

**List type:** Core (EML) (EMLc)

**Formulations:**
- **Oral > Liquid:** 125 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc); 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc)
- **Parenteral > General injections > unspecified:** 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- **Oral > Solid > dispersible tablet:** 250 mg (scored) (as trihydrate) (EMLc); 500 mg (scored) (as trihydrate) (EMLc)
- **Oral > Solid > dosage form:** 250 mg (as trihydrate); 500 mg (as trihydrate)

**EML status history:**
- First added in 2017 (TRS 1006)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Patents have expired in most jurisdictions

- Read more about patents.

- **Wikipedia:** Amoxicillin
- **DrugBank:** Amoxicillin

---

**Expert Committee recommendation**

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.

**EML recommendations: Acute sinusitis**

- **First choice**
- **Second choice**
amoxicillin

amoxicillin + clavulanic acid